Exodus Point Capital Management, LP Autolus Therapeutics PLC Transaction History

Exodus Point Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$2.32 - $3.36 $156,379 - $226,480	-67,405 Reduced 8.67%	710,355 $1.66 Million
Q2 2023 Aug 10, 2023	BUY	$1.64 - $3.21 $596,953 - $1.17 Million	363,996 Added 87.97%	777,760 $1.85 Million
Q1 2023 May 11, 2023	BUY	$1.75 - $2.25 $126,077 - $162,099	72,044 Added 21.08%	413,764 $761,000
Q4 2022 Feb 13, 2023	BUY	$1.74 - $3.27 $239,082 - $449,311	137,404 Added 67.25%	341,720 $649,000
Q3 2022 Nov 10, 2022	BUY	$2.04 - $3.76 $112,773 - $207,856	55,281 Added 37.09%	204,316 $437,000
Q2 2022 Aug 19, 2022	BUY	$2.04 - $4.68 $304,031 - $697,483	149,035 New	149,035 $422,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $272M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.